Fujino Haruhiko, Kondo Kazuya, Miyoshi Takanori, Ishikura Hisashi, Takahashi Yuji, Sawada Naruhiko, Hirose Yukiko, Takizawa Hiromitsu, Nagao Taeko, Sakiyama Shoji, Monden Yasumasa
Department of Oncological and Regenerative Surgery, School of Medicine, University of Tokushima, Tokushima, Japan.
Oncol Rep. 2003 Nov-Dec;10(6):1709-15.
In our previous studies, we established a lymphogenous metastatic SCID mouse model using orthotopic implantation of human lung cancer cell lines. However, the lymphogenous metastatic potential of each cell line in our models does not reflect that of a primary tumor. In this study, we made orthotopic implanted models using primary cultured cells from surgically-resected lung cancer tissues. Tissues of 5 patients with non-small cell lung cancer (NSCLC) were applied to a primary culture method using a collagen gel coated flask. Suspensions of 2.0x10(4) cancer cells were injected into the left lung of SCID mice. We could maintain primary culture cells from 2 (FM205 and FT821 cells) of 5 lung cancers, and made orthotopically implanted SCID mouse models. The size of both tumors in implanted sites of the lung increased with time. The FM205 cells microscopically were metastasized to the mediastinum by 4 weeks after implantation and macroscopically metastasized by 16 weeks. The FT821 cells were microscopically metastasized to the mediastinum by 4 weeks after implantation and macroscopically metastasized by 6 weeks. The lymphogenous metastatic potential of these primary culture cells was similar to that of clinical tumors. As the lymphogenous metastatic potential of this model reflects that of the clinical tumor, it is useful for elucidating the mechanism of lymphogenous metastasis and selecting anticancer drugs suitable for an individual patients.
在我们之前的研究中，我们通过原位植入人肺癌细胞系建立了一个淋巴道转移的SCID小鼠模型。然而，我们模型中每个细胞系的淋巴道转移潜能并不反映原发性肿瘤的转移潜能。在本研究中，我们使用手术切除的肺癌组织的原代培养细胞制作了原位植入模型。将5例非小细胞肺癌（NSCLC）患者的组织应用于使用胶原凝胶包被培养瓶的原代培养方法。将2.0×10⁴个癌细胞悬液注入SCID小鼠的左肺。我们能够维持5例肺癌中2例（FM205和FT821细胞）的原代培养细胞，并制作了原位植入的SCID小鼠模型。肺植入部位的两个肿瘤大小均随时间增加。FM205细胞在植入后4周镜下转移至纵隔，16周时肉眼可见转移。FT821细胞在植入后4周镜下转移至纵隔，6周时肉眼可见转移。这些原代培养细胞的淋巴道转移潜能与临床肿瘤相似。由于该模型的淋巴道转移潜能反映了临床肿瘤的转移潜能，因此它有助于阐明淋巴道转移机制并选择适合个体患者的抗癌药物。
